
Telmisartan (40mg) + Metoprolol Succinate (25mg)
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
The Nizatel Beta 25 Tablet ER is a combination medication consisting of Telmisartan (40mg) and Metoprolol Succinate (25mg). This extended-release formulation is designed for twice-daily administration. Telmisartan, an angiotensin II receptor blocker, assists in managing hypertension (high blood pressure) by reducing vascular tone and inhibiting angiotensin II-induced aldosterone secretion. Metoprolol Succinate, a beta-blocker, works by blocking the effects of epinephrine and norepinephrine on beta-adrenergic receptors in various organs, helping to reduce heart rate, blood pressure, and cardiac output. The combined action of these drugs offers a comprehensive approach to the management of hypertension, particularly in patients where monotherapy is insufficient or unsuitable. As with any medication, the use of Nizatel Beta 25 Tablet ER should be under the supervision of a healthcare professional.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Nizatel Beta 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Nizatel Beta 25 Tablet ER is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Nizatel Beta 25 Tablet ER is safe to use in patients with kidney disease. No dose adjustment of Nizatel Beta 25 Tablet ER is recommended.
Exercise Caution
Nizatel Beta 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Nizatel Beta 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Nizatel Beta 25 Tablet ER may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Nizatel Beta 25 Tablet ER

Telmisartan (40mg) + Metoprolol Succinate (25mg)
Cheaper alternative availability
This medicine doesn't have a cheaper alternative with the same composition. Our health advisors can help you find other savings options based on your prescription.
Active composition
+1 more active ingredient
Telmisartan selectively blocks angiotensin II receptors, leading to vasodilation and decreased blood pressure.
Metoprolol Succinate blocks beta-1 adrenergic receptors, leading to decreased heart rate and contractility, thereby lowering blood pressure.
Medical applications
The Nizatel Beta 25 Tablet ER is a combination medication consisting of Telmisartan (40mg) and Metoprolol Succinate (25mg). This extended-release formulation is designed for twice-daily administration. Telmisartan, an angiotensin II receptor blocker, assists in managing hypertension (high blood pressure) by reducing vascular tone and inhibiting angiotensin II-induced aldosterone secretion. Metoprolol Succinate, a beta-blocker, works by blocking the effects of epinephrine and norepinephrine on beta-adrenergic receptors in various organs, helping to reduce heart rate, blood pressure, and cardiac output. The combined action of these drugs offers a comprehensive approach to the management of hypertension, particularly in patients where monotherapy is insufficient or unsuitable. As with any medication, the use of Nizatel Beta 25 Tablet ER should be under the supervision of a healthcare professional.
Dosage information not available. Please consult your doctor or pharmacist.
Important precautions
Based on clinical trials and patient reports.
Overall Tolerance
Common Side Effects
Nizatel Beta 25 Tablet ER is unsafe to use during pregnancy as there is definite evidence of risk to the developing baby. However, the doctor may rarely prescribe it in some life-threatening situations if the benefits are more than the potential risks. Please consult your doctor.
High Risk
Nizatel Beta 25 Tablet ER is probably safe to use during breastfeeding. Limited human data suggests that the drug does not represent any significant risk to the baby.
Medical Advice
Nizatel Beta 25 Tablet ER is safe to use in patients with kidney disease. No dose adjustment of Nizatel Beta 25 Tablet ER is recommended.
Exercise Caution
Nizatel Beta 25 Tablet ER may decrease alertness, affect your vision or make you feel sleepy and dizzy. Do not drive if these symptoms occur.
Consult Doctor
Nizatel Beta 25 Tablet ER should be used with caution in patients with liver disease. Dose adjustment of Nizatel Beta 25 Tablet ER may be needed. Please consult your doctor.
Regular Checkup
0 reviews for Nizatel Beta 25 Tablet ER















